Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Clinical trial: Comparing hepatocellular cancer treatments

Radiofrequency thermal ablation is superior to percutaneous ethanol injection and percutaneous acetic acid injection with respect to local recurrence, overall survival, and cancer free survival rates, reports the latest issue of Gut.

News image

fiogf49gjkf04

Dr Lin and colleagues from Taiwan compared the outcomes of radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection in the treatment of hepatocellular carcinoma.

The investigators randomly assigned a total of 187 patients with hepatocellular carcinoma of 3 cm or less to 3 treatment groups.

The team randomized 62 patients radiofrequency thermal ablation, 62 to percutaneous ethanol injection, or 63 to percutaneous acetic acid injection.

The investigators assessed tumor recurrence and survival rates.

The team found that 1, 2, and 3 year local recurrence rates were 10%, 14%, and 14% in the radiofrequency thermal ablation group.

The 1, 2, and 3 year local recurrence rates were 16%, 34%, and 34% in the percutaneous ethanol injection group.

The 1 year survival rate in the radiofrequency thermal ablation group was 93%
Gut

The team also found that the 1, 2, and 3 year local recurrence rates were 14%, 31%, and 31% in the percutaneous acetic acid injection group.

The 1, 2, and 3 year survival rates were 93%, 81%, and 74% in the radiofrequency thermal ablation group.

For the percutaneous ethanol injection group, the 1, 2, and 3 year survival rates were 88%, 66%, and 51%.

The investigators also noted that the 1, 2, and 3 year survival rates were 90%, 67%, and 53% in the percutaneous acetic acid injection groups.

For the 1, 2, and 3 year cancer free survival rates, the team noted rates of 74%, 60%, and 43% in the radiofrequency thermal ablation group.

In the percutaneous ethanol injection group, the 1, 2, and 3 year cancer free survival rates were 70%, 41%, and 21%.

The team noted that 1, 2, and 3 year cancer survival rates were 71%, 43%, and 23% in the percutaneous acetic acid injection group.

Tumor size, tumor differentiation, and treatment methods were significant factors for local recurrence, overall survival, and cancer free survival.

The team reported that major complications occurred in 5% of patients, where 2 had haemothorax, 1 with gastric perforation in the radiofrequency thermal ablation group

No complications were observed in the 2 other groups.

Dr Lin's team concluded, “Radiofrequency thermal ablation was superior to percutaneous ethanol injection and percutaneous acetic acid injection with respect to local recurrence, overall survival, and cancer free survival rates, but radiofrequency thermal ablation also caused more major complications.”

Gut 2005: 54: 1151-6
18 July 2005

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us